Sphera Funds Management LTD. Reduces Position in Perspective Therapeutics, Inc. (NYSE:CATX)

Sphera Funds Management LTD. lessened its holdings in shares of Perspective Therapeutics, Inc. (NYSE:CATX - Free Report) by 21.9% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 460,247 shares of the company's stock after selling 129,048 shares during the quarter. Sphera Funds Management LTD. owned approximately 0.68% of Perspective Therapeutics worth $1,468,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. BNP Paribas Financial Markets raised its holdings in shares of Perspective Therapeutics by 7.4% during the fourth quarter. BNP Paribas Financial Markets now owns 51,094 shares of the company's stock valued at $163,000 after acquiring an additional 3,529 shares in the last quarter. Rhumbline Advisers raised its holdings in shares of Perspective Therapeutics by 4.5% during the fourth quarter. Rhumbline Advisers now owns 94,992 shares of the company's stock valued at $303,000 after acquiring an additional 4,075 shares in the last quarter. Bank of New York Mellon Corp raised its holdings in shares of Perspective Therapeutics by 3.4% during the fourth quarter. Bank of New York Mellon Corp now owns 143,469 shares of the company's stock valued at $458,000 after acquiring an additional 4,693 shares in the last quarter. JPMorgan Chase & Co. grew its stake in Perspective Therapeutics by 24.1% in the third quarter. JPMorgan Chase & Co. now owns 24,912 shares of the company's stock worth $333,000 after purchasing an additional 4,844 shares during the period. Finally, ProShare Advisors LLC grew its stake in Perspective Therapeutics by 49.1% in the fourth quarter. ProShare Advisors LLC now owns 15,225 shares of the company's stock worth $49,000 after purchasing an additional 5,011 shares during the period. Institutional investors own 54.66% of the company's stock.

Perspective Therapeutics Trading Up 3.8%

Shares of NYSE CATX traded up $0.10 during trading on Monday, reaching $2.73. The company had a trading volume of 1,549,650 shares, compared to its average volume of 1,029,980. Perspective Therapeutics, Inc. has a 12-month low of $1.60 and a 12-month high of $16.90. The business's 50-day moving average is $2.24 and its 200 day moving average is $3.59.

Insider Transactions at Perspective Therapeutics

In other Perspective Therapeutics news, Director Robert F. Williamson III acquired 38,145 shares of the company's stock in a transaction that occurred on Monday, March 31st. The shares were bought at an average cost of $2.14 per share, with a total value of $81,630.30. Following the completion of the transaction, the director now directly owns 108,982 shares of the company's stock, valued at approximately $233,221.48. This represents a 53.85% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Juan Graham acquired 33,333 shares of the company's stock in a transaction that occurred on Friday, March 28th. The shares were acquired at an average cost of $2.25 per share, for a total transaction of $74,999.25. Following the completion of the transaction, the chief financial officer now directly owns 35,354 shares of the company's stock, valued at $79,546.50. The trade was a 1,649.33% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last three months, insiders have purchased 115,696 shares of company stock valued at $256,344. Insiders own 3.72% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the company. Truist Financial reduced their price target on Perspective Therapeutics from $10.00 to $8.00 and set a "buy" rating on the stock in a research note on Wednesday, May 14th. Scotiabank assumed coverage on Perspective Therapeutics in a research note on Friday, March 7th. They issued a "sector outperform" rating and a $15.00 price target on the stock. Lifesci Capital raised Perspective Therapeutics to a "strong-buy" rating in a research note on Thursday, March 6th. Brookline Capital Management raised Perspective Therapeutics to a "strong-buy" rating in a research note on Monday, March 10th. Finally, Wedbush reaffirmed an "outperform" rating and issued a $11.00 price target on shares of Perspective Therapeutics in a research note on Tuesday, May 13th. One analyst has rated the stock with a hold rating, seven have assigned a buy rating and three have given a strong buy rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Buy" and an average target price of $12.50.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.